Thrasos Therapeutics, a Montreal, Canada-based biotherapeutics company focused on kidney disease, closed $21m in Series D funding.
The round was led by BDC Capital and SR One. In conjunction with the funding, Ela Borenstein, a manager partner at BDC, joined Thrasos’ board of directors.
The company intends to use the funds to both complete the ongoing 450-patient, Phase 2 study for its lead compound in Acute Kidney Injury (AKI) following cardiac surgery and extend its development programs into Chronic Kidney Disease (CKD).
Led by Richard Andrews, President and CEO, Thrasos Therapeutics focuses on delivering new solutions to individuals affected by kidney disease. The company’s lead compound, THR-184, is currently being evaluated in a Phase 2 clinical study for the prevention of Acute Kidney Injury (AKI) in patients undergoing cardiac surgery. The company is also developing compounds for diabetic nephropathy, a major cause of Chronic Kidney Disease.
Thrasos has a satellite office in Boston, Massachusetts.